Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

NCT00711828 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
21
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Mayo Clinic

Collaborators